Small molecule · Agonist of apelin receptor (APJ) (APLNR) · developed by BioAge Labs
Azelaprag (BGE-105) is an oral agonist of the apelin receptor (APJ), a G protein-coupled receptor. It is studied in healthy volunteers and in obesity.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06515418 | Phase 2 | Obesity | Terminated | BIOA |
| NCT06141889 | Phase 1 | Healthy Volunteer Study | Completed | BIOA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy Volunteer StudyObesity
Updated Nov 8, 2026. Something wrong or missing? Report it on the BIOA page.
See BIOA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BIOA catalysts and pipeline →